TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03002610

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pls
Description: Text format with simple explanation of the survey topic main findings and is intended for lay audience.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infographics
Description: Cochrane started developing infographics, where short textual information about research is supported by visual representations of the main findings and is also aimed at the lay public The investigators will examine whether this format is better in information uptake than standard PLS.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Scientific abstract
Description: Scientific abstract the text written for the academic population and practitioners, with scientific abbreviations which enables experts to go into more detail about the topic.
Study: NCT04367857

Intervention type: OTHER
Intervention: COVID-19 Serology
Description: Quantitate Serology enzyme-linked immunosorbent assay (ELISA) for COVID-19

Intervention type: OTHER
Intervention: COVID-19 Serology
Description: Quantitate Serology enzyme-linked immunosorbent assay (ELISA) for COVID-19

Intervention type: OTHER
Intervention: COVID-19 Serology
Description: Quantitate Serology enzyme-linked immunosorbent assay (ELISA) for COVID-19

Intervention type: OTHER
Intervention: COVID-19 Serology
Description: Quantitate Serology enzyme-linked immunosorbent assay (ELISA) for COVID-19

Intervention type: BEHAVIORAL
Intervention: Health Care Worker Survey
Description: The purpose of this survey is to assess how healthcare workers are experiencing and coping with the COVID-19 crisis.

Intervention type: BEHAVIORAL
Intervention: Health Care Worker Survey
Description: The purpose of this survey is to assess how healthcare workers are experiencing and coping with the COVID-19 crisis.

Intervention type: BEHAVIORAL
Intervention: Health Care Worker Survey
Description: The purpose of this survey is to assess how healthcare workers are experiencing and coping with the COVID-19 crisis.

Intervention type: BEHAVIORAL
Intervention: Health Care Worker Survey
Description: The purpose of this survey is to assess how healthcare workers are experiencing and coping with the COVID-19 crisis.
Study: NCT02694705

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Description: CPAP provided by a portable Draeger Oxylog® 3000 plus ventilator

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bag-Valve-Mask (BVM)
Description: Preoxygenation provided by BVM device, oxygen flow rate 15 l/min

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-rebreather Mask (NRM)
Description: Preoxygenation provided by NRM, oxygen flow rate 15 l/min
Study: NCT01429636

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Relaxation (MR)
Description: The MR technique is modified from the AR technique that will require participants to attend only 1 session, lasting 60 minutes. After the training session, participants will be given a hand-out on MR. They will continue to practice MR at home once a day for 15-20 minutes during their leisure times, at least 5 days a week for the whole 12 weeks of the follow-up period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Applied Relaxation (AR)
Description: Participants will receive 12 sessions AR training. After that they will asked to practice at home once a day for 15-20 minutes during their leisure times, at least 5 days a week for the whole 12 weeks of the follow-up period.
Study: NCT01355458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD07805/47 gel
Description: applied topically once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: applied topically once daily
Study: NCT02708979

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: University exam-period
Description: This visit takes place one week prior to an exam at the university assuming that students will be stressed in this period.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: University non-exam-period
Description: This visit takes place several weeks post and prior to an exam at the university assuming that students will not be stressed in this period.
Study: NCT03788538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: 10 minutes before anesthesia induction, all patients were administrated with dexmedetomidine 1 μg/kg/min.At the beginning of induction, dexmedetomidine was changed to corresponding maintenance dose in each group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: 10 minutes before anesthesia induction, all patients were administrated with dexmedetomidine 1 μg/kg/min.At the beginning of induction, dexmedetomidine was changed to corresponding maintenance dose in each group.
Study: NCT00530062

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol-HFA-MDI
Description: Inhalation Aerosols, 90 mcg, 1 dose per treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol-HFA-BAI
Description: Inhalation Aerosol (Breath-Actuated), 90 mcg, 1 dose per treatment period.
Study: NCT01822587

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol, 40 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol, 80 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02454192

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CHAMPS
Study: NCT03050502

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Chest tube drain
Description: This group will have an intra-pleural catheter placed with the intent of draining all intra-pleural blood (HTX). The size and nature of the catheter, manner of placement, and timing of removal will be at the discretion of the attending clinician.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Expectant management
Description: This group will not have an intra-pleural catheter placed on the basis of the HTX, but will undergo standard observation/conservative management by the trauma service. Intra-pleural catheters may be placed after enrollment at the attending clinician's discretion.
Study: NCT03964038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gilteritinib mini tablet
Description: oral
Study: NCT01655862

Intervention type: BIOLOGICAL
Intervention: OnabotulinumtoxinA
Description: OnabotulinumtoxinA injections at doses and frequencies as determined by the physician in accordance with clinical practice.
Study: NCT02253355

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Deep Brain Stimulation
Study: NCT03431402

Intervention type: DRUG
Group type: OTHER
Intervention: Hyperbaric oxygen
Description: - HBOT group will receive 10 sessions of HBOT at 2.0 Atmosphere absolute (ATA) for one hour in a hyperbaric chamber pressured with compressed air, whereby patients will breath 100% oxygen to 2 ATA started within 3-5days after the onset of stoke plus conventional therapy as antiplatelets therapy, correction of hypovolaemia , hypoxia and adequate nutrition
Study: NCT03879746

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: drug will be used in treatment of premature ejaculation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: drug will be used in treatment of premature ejaculation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine Hydrochloride
Description: drug will be used in treatment of premature ejaculation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine Hydrochloride
Description: drug will be used in treatment of premature ejaculation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: tablets without active substance will be given to patients suffering from premature ejaculation
Study: NCT04225533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP16
Description: All patients will receive a single dose of SP16
Study: NCT00708916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-10004
Description: 20 mg twice daily by mouth for 12 weeks, followed by a 4 week washout period and final assessment
Study: NCT03595332

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Summer activity program
Description: Children receive a summer scorecard to facilitate access to local facilities for exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Summer activity program
Description: Children receive a summer scorecard to facilitate access to local facilities for exercise.
Study: NCT00816465

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hoodia gordonii
Description: PO administration of 1 Tab Hoodia gordoni extract per day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PO Placebo pill
Study: NCT04110002

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Injury Prevention Program
Study: NCT04209478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride
Description: The Wong-Baker facial pain scale was used to assess pain (1: no pain, 10: worst possible pain). During monitoring patients with pain score ≥3 had intravenous 1 mg/kg tramadol hydrochloride administered, After 15 minutes following tramadol injection, cases with pain score continuing ≥3 were to be assessed as insufficient analgesia and had 0.1 mg/kg morphine hydrochloride planned for intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride
Description: The Wong-Baker facial pain scale was used to assess pain (1: no pain, 10: worst possible pain). During monitoring patients with pain score ≥3 had intravenous 1 mg/kg tramadol hydrochloride administered, After 15 minutes following tramadol injection, cases with pain score continuing ≥3 were to be assessed as insufficient analgesia and had 0.1 mg/kg morphine hydrochloride planned for intravenous administration
Study: NCT04563468

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Strength inspiratory muscle training
Description: Two training sessions per day consisting of 30 breaths (against external load of \~50% Pi,max; 4-5 minutes per session), 7 days/week (once/month supervised at the research center), for 6 months will be performed using an electronic tapered flow resistive loading (TFRL) device (POWERbreathe®KH1, HaB International Ltd., Southam, UK) according to an established method. Measurements of Pi,max will be performed every week and training loads will be increased continuously to maintain external load at \~50% of Pi,max values. Ratings of perceived inspiratory effort on a modified Borg scale (4-5 out of 10) will also be used to support decisions on increasing training load.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Endurance inspiratory muscle training
Description: Two daily sessions of 30 breaths using TFRL device (POWERbreathe®KH1, HaB International Ltd., Southam, UK) and will train at an inspiratory load of no more than 10% of their initial Pi,max. This training load will not be changed during the entire study period. Participants in the control group will be offered the active treatment upon completion of the study.
Study: NCT01089374

Intervention type: RADIATION
Group type: OTHER
Intervention: Partial breast radiation after lumpectomy
Description: Radiation therapy will be administered in the vicinity of the center where the surgical resection was performed. Adjuvant radiation must start within 12 weeks of breast excision or re-excision. The radiation oncologist can choose between two methods of partial breast irradiation (PBI): external beam partial breast radiation or Mammosite® brachytherapy, based on radiation oncologist and patient preference. Radiation will be administered per guidelines used in the NSABP B-39/RTOG 0413 protocol.
Study: NCT02657317

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FORT-A
Description: FORT-A is based on a functional restoration paradigm of pain management in which treatment is interdisciplinary and designed to achieve a functional goal (often specified by the patient; e.g., doing more with family, returning to work). FORT-A includes intensive functional rehabilitation, group-based pain management intervention, and individual interventions tailored to the patient's specific needs (e.g., biofeedback for stress, individual psychotherapy for mood or trauma symptoms).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VA Treatment as Usual
Description: VA TAU includes referrals for specialty intervention, rehabilitation, and behavioral health intervention within the VA medical system. Some participants may be referred for care outside of the VA system. The South Texas Veterans Health Care System offers a wide range of pain management services.
Study: NCT03786861

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: corneal WFG group
Description: TransPRK using ESIRIS flying spot excimer laser system (SCHWIND AMARIS®500E, SCHWIND eye-tech-solutions, Kleinhostheim, Germany), with 500 Hz repetition rate for faster treatments and scanning spots and with smart pulse technology. Eye-tracking during laser ablation was achieved using a 1050 Hz infrared eye tracker centered on the pupil. Static cyclotorsion control (SCC) compensation was obtained for all patients in corneal WFG group.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: corneal WFG group
Description: TransPRK using ESIRIS flying spot excimer laser system (SCHWIND AMARIS®500E, SCHWIND eye-tech-solutions, Kleinhostheim, Germany), with 500 Hz repetition rate for faster treatments and scanning spots and with smart pulse technology. Eye-tracking during laser ablation was achieved using a 1050 Hz infrared eye tracker centered on the pupil. Static cyclotorsion control (SCC) compensation was obtained for all patients in corneal WFG group.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: aberration free group
Description: TransPRK was performed to eligible myopic patients with or without astigmatism with corneal HOAs ≥ 0.35 µ utilizing aberration free patterns provided by ORKCAM software (SCHWIND eye-tech-solutions, Kleinostheim, Germany)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: aberration free group
Description: TransPRK was performed to eligible myopic patients with or without astigmatism with corneal HOAs ≥ 0.35 µ utilizing aberration free patterns provided by ORKCAM software (SCHWIND eye-tech-solutions, Kleinostheim, Germany)
Study: NCT00117676

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF
Description: 300 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF
Description: 300 mg tablet administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADV
Description: 10 mg tablet administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF placebo
Description: Tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADV placebo
Description: Tablet administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FTC/TDF
Description: 200/300 mg fixed-dose combination (FDC) tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TDF
Description: 200/300 mg fixed-dose combination (FDC) tablet administered orally once daily
Study: NCT04710745

Intervention type: DIAGNOSTIC_TEST
Intervention: Peripheral blood samples for routine analysis including NT-proBNP and plasmatic biomarkers.
Description: Sampling of peripheral venous blood for analysis of plasma concentration of plasmatic markers (Apelin, microRNA, FGF-23, IGF-1, IGFBP-1) and routine analysis (laboratory parameters: NT-proBNP, D-dimer, Creatinine Clearance, CRP, Hs-troponin).

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: ECHO parameters:~* E/e´~* Mean e' septal and lateral wall~* LA volume (Biplane Area-Length Method)~* Left atrial volume index~* Diameter of left atrium in PLAX~* Severe aortic stenosis~* Severe mitral regurgitation~* Severe tricuspid regurgitation~* Left ventricular end-diastolic diameter~* Interventricular septum~* Posterior wall~* LV Mass~* Left ventricular mass index

Intervention type: DIAGNOSTIC_TEST
Intervention: ECG Holter monitor
Description: Patient receives an ECG Holter for a 7-day monitoring.

Intervention type: DIAGNOSTIC_TEST
Intervention: Standardized Mini-Mental Status Exam (SMMSE)
Description: A screening test for evaluating cognitive performance of patients done in the clinician's office.
Study: NCT02216266

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physostigmine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride solution
Study: NCT04934579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375mg/m2 intravenous infusion d1, every 3 weeks for 1 cycle, 6 cycles will be prescribed for induction therapy. 375mg/m2 intravenous infusion d1, every 8 weeks for 1 cycle, 4 cycles will be prescribed for maintenance therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25mg orally d1-10 every 3 weeks for 1 cycle, 6 cycles will be prescribed for induction therapy. 25mg orally d1-14,d29-42 every 8 weeks for 1 cycle, 4 cycles will be prescribed for maintenance therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 3.5g/m2 intravenous infusion for 4 hours in d1, every 21 days for 1 cycle, 6 cycles will be prescribed.
Study: NCT03720938

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Video Games
Description: Nintendo Wii® AVGs from sports, balance, aerobics, resort and training categories.
Study: NCT01155154

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cephalexin
Description: 500 mg (two 250 mg capsules) every 6 hours for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clindamycin
Description: 300 mg of clindamycin (two 150 mg capsules) every 6 hours for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Two placebo capsules every 6 hours for 7 days
Study: NCT01209585

Intervention type: OTHER
Intervention: Synovial tissue sample
Description: Subjects will have visits on Days 1, 30, and 120.
Study: NCT01152346

Intervention type: DRUG
Group type: OTHER
Intervention: Azacitidine for Injection
Description: 75 mg/m2 sc injection on Day 1 of either cycle 1 or cycle 2 per randomization assignment
Study: NCT02320292

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Yttrium Y-90 Ibritumomab Tiuxetan
Description: Given IV
Study: NCT01152346

Intervention type: DRUG
Group type: OTHER
Intervention: Azacitidine for Injection
Description: 75 mg/m2 sc injection on Day 1 of either cycle 1 or cycle 2 per randomization assignment

Intervention type: DRUG
Group type: OTHER
Intervention: Vidaza®
Description: 75 mg/m2 sc injection on Day 1 of either cycle 1 or cycle 2 per randomization assignment

Intervention type: DRUG
Group type: OTHER
Intervention: Vidaza®
Description: 75 mg/m2 sc injection on Day 1 of either cycle 1 or cycle 2 per randomization assignment
Study: NCT01256164

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fibrocaps (fibrin sealant)
Description: Fibrocaps powder (max dose 1.5g) should be applied directly to the bleeding site or to the Gelfoam and then applied to the bleeding site. Re-application of 1.5 g of Fibrocaps is allowed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gelfoam
Description: An identified Target Bleeding Site (TBS) should be treated with application of Gelfoam followed by light manual pressure with a sterile gauze.
Study: NCT00199238

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rupatadine Fumarate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rupatadine Fumarate
Study: NCT05742828

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Seating Coach
Description: Power wheelchair intervention
Study: NCT04437433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atogepant 60 mg
Description: Tablets containing 60 mg atogepant
Study: NCT02470494

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sound amplification provided via the EarLens CHD
Description: Subjects with mild to severe hearing impairment receiving sound amplification treatment with EarLens CHD.
Study: NCT00199238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rupatadine Fumarate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rupatadine Fumarate
Study: NCT00904761

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise training
Description: The exercise group took supervised aerobic training twice per week at hospital and thrice per week at home for eight weeks at the intensity of 60-70% VO2peak
Study: NCT02177916

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Study: NCT02710812

Intervention type: PROCEDURE
Intervention: Local Excision or Wait-and-See
Description: Local excision can be done both with traditional technique and with endoscopic technique (TEM, TAMIS, etc.).~The following principles should be respected:~1. A gross margin of at least 0.5 cm;~2. full-thickness excision including mucosa, submucosa, muscle and peri-rectal fat;~3. determination of the specimen on the support by pins at the edges in order to facilitate the interpretation of histological pathologist.
Study: NCT02915848

Intervention type: DEVICE
Intervention: PC+S group
Description: PC+S group: participants in the study will also receive a specific stimulation device (Activa PC+S, Medtronic) that is capable of recording the local field potentials (LFP). Approximately 10 participants are expected to take part in this study at UHN.
Study: NCT01756911

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MFM
Description: Implantation of the MFM
Study: NCT01497522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: vildagliptin 50 mg twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo of vildagliptin 50 mg twice daily
Study: NCT03072940

Intervention type: OTHER
Intervention: Clinical investigations
Description: Clinical examination, motor, cognitive, autonomous, psychological, olfactory and color vision tests, and rapid eye movement sleep characterization using video-polysomnography and 3 T magnetic resonance imaging

Intervention type: OTHER
Intervention: Clinical investigations
Description: Clinical examination, motor, cognitive, autonomous, psychological, olfactory and color vision tests, and rapid eye movement sleep characterization using video-polysomnography and 3 T magnetic resonance imaging